Cell behavior
ROCK2 is a downstream target of RhoA and mediates myosin light chain phosphorylation, processes that are key to smooth muscle cell proliferation, fibroblast activation and vascular remodeling.
Science
Rho associated protein kinase 2 (ROCK2) is a serine/threonine protein kinase that helps regulate fibrosis, inflammation, vascular remodeling and central nervous system maturation. These processes are central to how blood vessels and the heart respond to stress and participate in the pathogenesis of multiple cardiac disease processes.
ROCK2 is a downstream target of RhoA and mediates myosin light chain phosphorylation, processes that are key to smooth muscle cell proliferation, fibroblast activation and vascular remodeling.
ROCK2 selectivity is key to avoiding some of the counter effects of ROCK1 inhibition and to avoiding some of the side effects of pan-ROCK inhibitors.
In cardiac tissue and pulmonary vasculature, there is greater expression of ROCK 2 vs ROCK1. The pathologic effects of ROCK 2 activation are most important for cardiopulmonary indications such as pulmonary arterial hypertension, heart failure with preserved ejection fraction, and additional cardiomyopathies.
Mechanism
In the heart, fibroblast-specific ROCK2 inhibition has been shown to reduce fibrosis and improve diastolic dysfunction. In the lung and pulmonary vasculature, ROCK inhibition decreased collagen deposition and fibrosis. ROCK2 signaling links TGF-β and mechanical stress to fibroblast activation, actin remodeling, and extracellular matrix production. Inhibiting ROCK2 can reduce myofibroblast differentiation, CTGF (Connective Tissue Growth Factor) expression, and collagen deposition.
ROCK2 inhibition has been shown to decrease inflammatory-cell recruitment and cytokine release, potentially reducing immune-driven activation of cardiac and pulmonary fibroblasts. ROCK2 regulates immune-cell activity through pathways including STAT3 and STAT5, which help set the balance between inflammatory and regulatory T-cell responses. Selective ROCK2 inhibition also reduces the production of IL-17 and IL-21, two key pro-inflammatory cytokines.
ROCK2 drives pathological cardiac growth through cardiomyocyte signaling and fibroblast-derived growth factors. In pulmonary vessels, ROCK2 inhibition suppresses smooth-muscle proliferation and remodeling. Antagonizing ROCK2 in cardiomyocytes increased FHL2-associated restraint of SRF/ERK signaling and reduced hypertrophy after angiotensin II exposure or pressure overload.
Focus
Indication
Pulmonary arterial hypertension is a debilitating and potentially lethal disease with limited treatment options. Most drugs for PAH have severe side effects, are difficult to administer and do not treat the underlying pathophysiology of fibrosis and vascular smooth muscle proliferation. ROCK 2 inhibition has the potential to get to the root cause of the disease. An oral drug that has limited side effects could revolutionize treatment options.
Indication
HFpEF is the most common type of heart failure but has limited treatment options. ROCK 2 inhibition can potentially treat the fibrosis, inflammation, myocyte hypertrophy, as well as the metabolic derangements that are the classic hallmarks of HFpEF. A single agent that could target fibrosis, inflammation, hypertrophy and also the underlying metabolism associated with HFpEF would be a long-sought goal in the treatment of HFpEF.
Indication
ROCK inhibition can improve cardiac fibrosis by preventing fibroblast transition to myofibroblasts, prevent left ventricular hypertrophy, and improve microvascular coronary flow. While antagonists of the renin-angiotensin-aldosterone system have formed the backbone of therapy for many cardiomyopathies, the actions of angiotensin II on myocytes have also been hypothesized to be dependent on the ROCK 2 pathway.
Source: gravitoncorp.com/pipeline. Development stages as published by Graviton Bioscience; CinRock program details pending confirmation.
Currently conducting multiple animal studies with selective ROCK2 Inhibitors in pulmonary hypertension, HFpEF and other cardiovascular diseases.